Literature DB >> 21740937

Construction and characterization of human adenovirus serotype 3 packaged by serotype 7 hexon.

Xingui Tian1, Xiaobo Su, Haitao Li, Xiao Li, Zhichao Zhou, Wenkuan Liu, Rong Zhou.   

Abstract

Human adenovirus serotype 3 (Ad3) and serotype 7 (Ad7) are important pathogens causing respiratory tract diseases such as acute respiratory disease in pediatric and adult patients, but the immunodominant targets of Ad3- and Ad7-specific neutralizing antibodies (NAbs) remain unclear. A chimeric Ad vector, Ad3/H7, was constructed by replacing the Ad3 hexon gene (H3) with the hexon gene (H7) of Ad7. The chimeric viruses were successfully rescued in HEp-2 cells, and the Ad7 hexon was able to encapsidate the Ad3 genome, and functioned as efficiently as the Ad3 hexon. Furthermore, we tested the host neutralization responses against the viruses using BALB/C mice. Up to 97% of the NAbs produced by mice that were infected with these viruses were specific for the hexon protein in vitro. Preimmunization of mice with one of Ad7 and Ad3/H7 significantly prevented subsequent intranasal infection of the other type in vivo. In contrast, preimmunization of mice with one of Ad3 and Ad3/H7 did not remarkably prevent subsequent infection of the other type. We next evaluated the functional significance of hexon and other structural proteins specific NAbs to suppress the immunogenicity of Ad3/H3 and Ad3/H7 vectors expressing EGFP in mice preimmunized with wild type Ad. Preimmunization of mice with Ad7 evidently suppressed EGFP-specific humoral immune responses elicited by Ad3/H7, and did not exert suppressive effects on Ad3/H3. But contrary to the in vitro neutralization results, EGFP-specific humoral immune responses elicited by Ad3/H7 was remarkably inhibited in Ad3-preimmunization mice. The whole genome of the Ad7 strain was sequenced and aligned with Ad3. The major differences between Ad3 and Ad7 were only observed in the fiber and hexon among all structural proteins, and the variation between the hexons only located in four hypervariable regions (HVRs), HVR-1, -2, -5, and -7. These results thus suggest that Ad3- and Ad7-specific NAbs are directed primarily against the hexon proteins both in vitro and in vivo. But high titer Ad3 fiber-specific NAbs may also play an important role in blunting Ad3 immunogenicity in vivo. These studies contribute to a more profound understanding of Ad immunogenicity and have relevance for the design of novel Ad vaccine.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21740937     DOI: 10.1016/j.virusres.2011.06.017

Source DB:  PubMed          Journal:  Virus Res        ISSN: 0168-1702            Impact factor:   3.303


  16 in total

1.  Antigenic variability among two subtypes of human adenovirus serotype 7.

Authors:  Xingui Tian; Xiaobo Su; Chunyan Xue; Xiao Li; Zhichao Zhou; Rong Zhou
Journal:  Virus Genes       Date:  2014-04-24       Impact factor: 2.332

Review 2.  Vaccine development for human mastadenovirus.

Authors:  Shiying Chen; Xingui Tian
Journal:  J Thorac Dis       Date:  2018-07       Impact factor: 2.895

3.  Utilizing the antigen capsid-incorporation strategy for the development of adenovirus serotype 5-vectored vaccine approaches.

Authors:  Linlin Gu; Anitra L Farrow; Alexandre Krendelchtchikov; Qiana L Matthews
Journal:  J Vis Exp       Date:  2015-05-06       Impact factor: 1.355

4.  Serotype-specific neutralizing antibody epitopes of human adenovirus type 3 (HAdV-3) and HAdV-7 reside in multiple hexon hypervariable regions.

Authors:  Hongling Qiu; Xiao Li; Xingui Tian; Zhichao Zhou; Ke Xing; Haitao Li; Ni Tang; Wenkuan Liu; Peisheng Bai; Rong Zhou
Journal:  J Virol       Date:  2012-05-23       Impact factor: 5.103

5.  Molecular evolution of human adenovirus type 16 through multiple recombination events.

Authors:  Xingui Tian; Hongkai Wu; Rong Zhou
Journal:  Virus Genes       Date:  2019-08-05       Impact factor: 2.332

Review 6.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

7.  Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection.

Authors:  Anitra L Farrow; Girish Rachakonda; Linlin Gu; Valentina Krendelchtchikova; Pius N Nde; Siddharth Pratap; Maria F Lima; Fernando Villalta; Qiana L Matthews
Journal:  PLoS Negl Trop Dis       Date:  2014-08-21

8.  Human Adenovirus Serotype 3 Vector Packaged by a Rare Serotype 14 Hexon.

Authors:  Xiaobo Su; Xingui Tian; Zaixue Jiang; Qiang Ma; Qian Liu; Xiaomei Lu; Rong Zhou
Journal:  PLoS One       Date:  2016-06-21       Impact factor: 3.240

9.  Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.

Authors:  Xingui Tian; Xiaobo Su; Xiao Li; Haitao Li; Ting Li; Zhichao Zhou; Tianhua Zhong; Rong Zhou
Journal:  PLoS One       Date:  2012-07-27       Impact factor: 3.240

10.  Generation of neutralizing monoclonal antibodies against a conformational epitope of human adenovirus type 7 (HAdv-7) incorporated in capsid encoded in a HAdv-3-based vector.

Authors:  Minglong Liu; Xingui Tian; Xiao Li; Zhichao Zhou; Chenyang Li; Rong Zhou
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.